scholarly journals Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling

2012 ◽  
Vol 10 (5) ◽  
pp. 595-609 ◽  
Author(s):  
Shila Mekhoubad ◽  
Christoph Bock ◽  
A. Sophie de Boer ◽  
Evangelos Kiskinis ◽  
Alexander Meissner ◽  
...  
2017 ◽  
Vol 381 ◽  
pp. 858
Author(s):  
T. Mishima ◽  
T. Ishikawa ◽  
K. Imamura ◽  
T. Kondo ◽  
Y. Koshiba ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 2698
Author(s):  
Ishnoor Sidhu ◽  
Sonali P. Barwe ◽  
Raju K. Pillai ◽  
Anilkumar Gopalakrishnapillai

In vitro modeling of hematological malignancies not only provides insights into the influence of genetic aberrations on cellular and molecular mechanisms involved in disease progression but also aids development and evaluation of therapeutic agents. Owing to their self-renewal and differentiation capacity, induced pluripotent stem cells (iPSCs) have emerged as a potential source of short in supply disease-specific human cells of the hematopoietic lineage. Patient-derived iPSCs can recapitulate the disease severity and spectrum of prognosis dictated by the genetic variation among patients and can be used for drug screening and studying clonal evolution. However, this approach lacks the ability to model the early phases of the disease leading to cancer. The advent of genetic editing technology has promoted the generation of precise isogenic iPSC disease models to address questions regarding the underlying genetic mechanism of disease initiation and progression. In this review, we discuss the use of iPSC disease modeling in hematological diseases, where there is lack of patient sample availability and/or difficulty of engraftment to generate animal models. Furthermore, we describe the power of combining iPSC and precise gene editing to elucidate the underlying mechanism of initiation and progression of various hematological malignancies. Finally, we discuss the power of iPSC disease modeling in developing and testing novel therapies in a high throughput setting.


2017 ◽  
Vol 35 (1) ◽  
pp. 77-94 ◽  
Author(s):  
Alec S.T. Smith ◽  
Jesse Macadangdang ◽  
Winnie Leung ◽  
Michael A. Laflamme ◽  
Deok-Ho Kim

Cells ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1953
Author(s):  
Robert F. Halliwell ◽  
Hamed Salmanzadeh ◽  
Leanne Coyne ◽  
William S. Cao

Human stem cell-derived neurons are increasingly considered powerful models in drug discovery and disease modeling, despite limited characterization of their molecular properties. Here, we have conducted a detailed study of the properties of a commercial human induced Pluripotent Stem Cell (iPSC)-derived neuron line, iCell [GABA] neurons, maintained for up to 3 months in vitro. We confirmed that iCell neurons display neurite outgrowth within 24 h of plating and label for the pan-neuronal marker, βIII tubulin within the first week. Our multi-electrode array (MEA) recordings clearly showed neurons generated spontaneous, spike-like activity within 2 days of plating, which peaked at one week, and rapidly decreased over the second week to remain at low levels up to one month. Extracellularly recorded spikes were reversibly inhibited by tetrodotoxin. Patch-clamp experiments showed that iCell neurons generated spontaneous action potentials and expressed voltage-gated Na and K channels with membrane capacitances, resistances and membrane potentials that are consistent with native neurons. Our single neuron recordings revealed that reduced spiking observed in the MEA after the first week results from development of a dominant inhibitory tone from GABAergic neuron circuit maturation. GABA evoked concentration-dependent currents that were inhibited by the convulsants, bicuculline and picrotoxin, and potentiated by the positive allosteric modulators, diazepam, chlordiazepoxide, phenobarbital, allopregnanolone and mefenamic acid, consistent with native neuronal GABAA receptors. We also show that glycine evoked robust concentration-dependent currents that were inhibited by the neurotoxin, strychnine. Glutamate, AMPA, Kainate and NMDA each evoked concentration-dependent currents in iCell neurons that were blocked by their selective antagonists, consistent with the expression of ionotropic glutamate receptors. The NMDA currents required the presence of the co-agonist glycine and were blocked in a highly voltage-dependent manner by Mg2+ consistent with the properties of native neuronal NMDA receptors. Together, our data suggest that such human iPSC-derived neurons may have significant value in drug discovery and development and may eventually largely replace the need for animal tissues in human biomedical research.


Author(s):  
Katharina Janssen ◽  
Lamiaa Bahnassawy ◽  
Claudia Kiefer ◽  
Jürgen Korffmann ◽  
Georg C. Terstappen ◽  
...  

Science ◽  
2012 ◽  
Vol 338 (6111) ◽  
pp. 1155-1156 ◽  
Author(s):  
F. Soldner ◽  
R. Jaenisch

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Kenji Miki ◽  
Kohei Deguchi ◽  
Misato Nakanishi-Koakutsu ◽  
Antonio Lucena-Cacace ◽  
Shigeru Kondo ◽  
...  

AbstractOne of the earliest maturation steps in cardiomyocytes (CMs) is the sarcomere protein isoform switch between TNNI1 and TNNI3 (fetal and neonatal/adult troponin I). Here, we generate human induced pluripotent stem cells (hiPSCs) carrying a TNNI1EmGFP and TNNI3mCherry double reporter to monitor and isolate mature sub-populations during cardiac differentiation. Extensive drug screening identifies two compounds, an estrogen-related receptor gamma (ERRγ) agonist and an S-phase kinase-associated protein 2 inhibitor, that enhances cardiac maturation and a significant change to TNNI3 expression. Expression, morphological, functional, and molecular analyses indicate that hiPSC-CMs treated with the ERRγ agonist show a larger cell size, longer sarcomere length, the presence of transverse tubules, and enhanced metabolic function and contractile and electrical properties. Here, we show that ERRγ-treated hiPSC-CMs have a mature cellular property consistent with neonatal CMs and are useful for disease modeling and regenerative medicine.


Sign in / Sign up

Export Citation Format

Share Document